The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor.
 
Jessica Tao
No Relationships to Disclose
 
Ruizhe Chen
No Relationships to Disclose
 
Amanda L. Blackford
No Relationships to Disclose
 
Terrence Cescon
No Relationships to Disclose
 
Antonios Christou
No Relationships to Disclose
 
Rima Couzi
No Relationships to Disclose
 
Elizabeth Darga
No Relationships to Disclose
 
Mary Kate Jones
No Relationships to Disclose
 
Justin Mahosky
No Relationships to Disclose
 
Raquel Nunes
Employment - AstraZeneca
 
Costanza Paoletti
Employment - Eisai
 
Cesar Augusto Santa-Maria
Consulting or Advisory Role - Athenex; Bristol-Myers Squibb; Genomic Health; Halozyme; Merck; Pfizer; Pfizer; Polyphor; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Medimmune (Inst); Merck (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst)
 
Karen L. Smith
Employment - AstraZeneca
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbvie (I); AstraZeneca; AstraZeneca
Research Funding - Pfizer (Inst)
 
Cristina I. Truica
Stock and Other Ownership Interests - GlaxoSmithKline
Honoraria - Daiichi Sankyo/Lilly; Puma Biotechnology; Seagen
Consulting or Advisory Role - Novartis
Speakers' Bureau - Daiichi Sankyo/Lilly; Puma Biotechnology; Seagen; Seagen
Research Funding - Novartis
 
Jeanine Werner
No Relationships to Disclose
 
Antonio C. Wolff
Research Funding - Array BioPharma (Inst); Genentech (Inst); Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Vered Stearns
Consulting or Advisory Role - Novartis
Research Funding - Abbvie (Inst); Biocept (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Other Relationship - AstraZeneca
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion
Honoraria - Tempus
Consulting or Advisory Role - BioVica; Cellworks; Cepheid; Epic Sciences; Exact Sciences; Freenome; Guardant Health; L-Nutra; Macrogenics; Oncocyte; Predictus Biosciences; Tempus; Turnstone Bio; xilis
Research Funding - AstraZeneca (Inst); Cepheid/Danaher (Inst); Menarini Silicon Biosystems (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Other Relationship - Menarini; UpToDate
(OPTIONAL) Uncompensated Relationships - UpToDate